Endothelial nitric oxide synthase gene intron 4 polymorphism predicts new onset diabetes mellitus after transplantation in kidney allograft recipients treated with cyclosporin A

Ergun, Ihsan; Keven, Kenan; Şengül, Şule; Karabulut, Halil Gürhan; Kurultak, İlhan; Soypaçacı, Zeki; Erbay, Bülent

doi:10.1007/s11255-010-9786-8

Cited by 8 publications

(1 citation statement)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Recently, the influence of genetic polymorphisms on the development of NODAT after kidney transplantation has been described, especially Type 2 diabetes susceptibility genes ( Table 2) [39][40][41][42][43][44][45][46][47][48][49][50]. Of these, some seem to increase the risk of NODAT, while others may be protective.…”

Section: Genetic Factorsmentioning

confidence: 99%

Cellular and physiological mechanisms of new‐onset diabetes mellitus after solid organ transplantation

et al. 2012

View full text Add to dashboard Cite

New-onset diabetes after transplantation is recognized as one of the metabolic consequences which may increase the risk of morbidity and mortality after solid organ transplantation. The pathophysiology of new-onset diabetes after transplantation has not been clearly defined and may resemble that of Type 2 diabetes, characterized by predominantly insulin resistance or defective insulin secretion, or both. This review aims to summarize the current state of knowledge regarding the prevalence, consequences, pathogenesis, and management of new-onset diabetes after transplantation, with a major focus on the possible mechanisms involved in the pathogenesis of the disorder. The aetiology of new-onset diabetes after transplantation is multifactorial, with diabetogenic immunosuppressive drugs playing a major role. Multiple cellular and physiologic mechanisms are involved in the process. Selection of an appropriate maintenance immunosuppressive regimen should involve balancing the risk of patient and graft survival vs. the potential for new-onset diabetes after transplantation.Diabet. Med. 29, e1-e12 (2012)

show abstract

Section: Genetic Factorsmentioning

confidence: 99%

Cellular and physiological mechanisms of new‐onset diabetes mellitus after solid organ transplantation

et al. 2012

View full text Add to dashboard Cite

show abstract

Prevalence of new-onset diabetes mellitus after kidney transplantation: a systematic review and meta-analysis

Du,

Li,

et al. 2024

Acta Diabetol

View full text Add to dashboard Cite

Drug-induced hyperglycaemia and diabetes: pharmacogenomics perspectives

Liu

et al. 2018

Arch. Pharm. Res.

View full text Add to dashboard Cite

Drug-induced diabetes is widely reported in clinical conditions, and it is becoming a global issue because of its potential to increase the risk of severe cardiovascular complications. However, which drug mechanisms exert their diabetogenic effects and why the effects present significant inter-individual differences remain largely unknown. Pharmacogenomics, which is the study of how genomic variation influences drug responses, provides an explanation for individual differences in drug-induced diabetes. We highlight that pharmacogenomics can be involved in regulating the expression of genes in signaling pathways related to the pharmacokinetics or pharmacodynamics of drugs or the pathogenesis of diabetes, contributing to the differences in drug-induced glucose impairment. The pharmacogenomics studies of the major diabetogenic drugs are reviewed, including calcineurin inhibitors, antipsychotics, hormones, and antihypertensive drugs. We intend to elucidate the genetic basis of drug-induced diabetes and pave the way for the precise use of these drugs in the clinic.

show abstract

Endothelial nitric oxide synthase gene intron 4 polymorphism predicts new onset diabetes mellitus after transplantation in kidney allograft recipients treated with cyclosporin A

Abstract: These findings suggest that carrying a 4a allele of the eNOS gene intron 4 polymorphism is associated with NODAT. This may help us to further understand the individual risk for development of NODAT in kidney allograft recipients under CsA treatment.

Cited by 8 publications

References 19 publications

Cellular and physiological mechanisms of new‐onset diabetes mellitus after solid organ transplantation

Cellular and physiological mechanisms of new‐onset diabetes mellitus after solid organ transplantation

Prevalence of new-onset diabetes mellitus after kidney transplantation: a systematic review and meta-analysis

Drug-induced hyperglycaemia and diabetes: pharmacogenomics perspectives

Contact Info

Product

Resources

About